Sarah Aebersold - 24 Feb 2026 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Role: Chief Human Resources Officer
Signature: /s/ Sarah Aebersold
Issuer symbol: BLFS
Transactions as of: 24 Feb 2026
Net transactions value: -$129,875
Form type: 4
Filing time: 26 Feb 2026, 17:55:29 UTC
Previous filing: 08 Jan 2026
Next filing: 05 Mar 2026
SEC: View on sec.gov

Quoteable Key Fact

"Sarah Aebersold filed Form 4 for BIOLIFE SOLUTIONS INC (BLFS) on 26 Feb 2026."

Quick Takeaways

This page summarizes Sarah Aebersold's Form 4 filing for BIOLIFE SOLUTIONS INC (BLFS).
2 reported transactions and 0 derivative rows are listed below.
Filing timestamp: 26 Feb 2026, 17:55.

What Changed

Previous filing in this sequence was filed on 08 Jan 2026.
Current net transaction value: -$129,875.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Aebersold Sarah	Chief Human Resources Officer	3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL	/s/ Sarah Aebersold	26 Feb 2026	0001837756

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BLFS	Common Stock	Award		+23,548	+31%		99,313	24 Feb 2026	Direct	F1
transaction	BLFS	Common Stock	Tax liability	$129,875	-5,734	-5.8%	$22.65	93,579	24 Feb 2026	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F2	Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.

Content

The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.